2021
DOI: 10.1161/circresaha.121.318051
|View full text |Cite
|
Sign up to set email alerts
|

Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients

Abstract: The development of a wide range of novel antineoplastic therapies has improved the prognosis for patients with a wide range of malignancies, which has increased the number of cancer survivors substantially. Despite the oncological benefit, cancer survivors are exposed to short- and long-term adverse cardiovascular toxicities associated with anticancer therapies. Systemic hypertension, the most common comorbidity among cancer patients, is a major contributor to the increased risk for developing these adverse ca… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
118
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 85 publications
(120 citation statements)
references
References 218 publications
1
118
0
1
Order By: Relevance
“…In 2019, more than 16.9 million Americans with a history of cancer were alive, and this number is projected to grow to more than 22.1 million by 2030 ( 23 ). The development of novel anticancer drugs has significantly contributed to increased survival rates for patients with cancer over recent decades and comes at the cost of potential short-term and long-term toxicities ( 24 ). Cardiovascular toxicity is nonnegligible and adversely affects outcomes ( 25 ).…”
Section: Discussionmentioning
confidence: 99%
“…In 2019, more than 16.9 million Americans with a history of cancer were alive, and this number is projected to grow to more than 22.1 million by 2030 ( 23 ). The development of novel anticancer drugs has significantly contributed to increased survival rates for patients with cancer over recent decades and comes at the cost of potential short-term and long-term toxicities ( 24 ). Cardiovascular toxicity is nonnegligible and adversely affects outcomes ( 25 ).…”
Section: Discussionmentioning
confidence: 99%
“…VSP inhibitors could cause depletion of nitric oxide and prostacyclin which are vasodilators as well as increased vasoconstrictive endothelin-1 ( 89 ). In addition, increased reactive oxygen species, functional decreased microvascular density, increased vascular stiffness, and salt sensitivity are other possible reasons ( 90 ).…”
Section: Treatment Of Rcc Cause Htnmentioning
confidence: 99%
“…However, HTN that is not induced by targeted therapy could increase the risk of RCC mortality ( OR = 1.75, 95% CI : 1.61–1.90) demonstrated by a review such as 6,964 patients of RCC in 2002 ( 91 ). Severe HTN in patients of RCC could cause HF, leukoencephalopathy, suspend, or cessation of targeted drugs ( 75 , 90 ), which will do harm to the prognosis and well-control of BP during targeted therapy could improve prognosis ( 92 ).…”
Section: Treatment Of Rcc Cause Htnmentioning
confidence: 99%
“…However, in contrast with the early situation with trastuzumab, the importance of VEGF in cardiovascular haemostasis and development had been well described for decades prior to therapeutic targeting. It is, therefore, not surprising that anti-VEGF drugs are strongly associated with unwanted cardiovascular effects including hypertension [ 7 , 8 ] and left ventricular dysfunction [ 9 ] which, at least partly, reflects microvascular dysfunction. It is notable that other therapies, including targeted inhibition of rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) for the treatment of cutaneous melanoma are also associated with a broad range of toxicities [ 10 ].…”
Section: Targeted Therapiesmentioning
confidence: 99%